drugset
drugset / Trial / NCT05532293

Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers

NCT05532293 ↗

Phase 1 Completed 64 enrolled Godavari Biorefineries Limited
RandomizedParallel-groupTriple-blindBasic science

Summary

This is a Phase I clinical study of MSP008-22, the Investigational Medicinal Product (IMP). The current study is designed to evaluate the safety and tolerability and pharmacokinetics of single and multiple oral doses of the IMP (MSP008-22) in healthy volunteers.

Timeline

Start
2022-12-02
Primary completion
2025-11-10
Completion
2025-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MSP008-22 Small molecule 200 mg Oral
Subject MSP008-22 Small molecule 400 mg Oral
Subject MSP008-22 Small molecule 600 mg Oral
Subject MSP008-22 Small molecule 800 mg Oral
Subject MSP008-22 Small molecule 1000 mg Oral

Indications

COVID-19